The Ladies Professional Golf Association, LPGA, and Ardelyx (ARDX) announced a multi-year partnership naming Ardelyx as an official corporate pharmaceutical Marketing Partner of the LPGA Tour. The exclusive partnership unites two organizations dedicated to empowering women to take control of their health. “This partnership represents a natural alignment between Ardelyx’s mission and the LPGA’s platform to support the digestive health of women, who account for more than 90 percent of those living with conditions like irritable bowel syndrome with constipation, yet many suffer in silence due to stigma and lack of awareness,” said Eric Foster, chief commercial officer of Ardelyx. “By partnering with the LPGA, we will engage with our shared audience, not just as golf fans, but as individuals who deserve open conversations about their health. At the heart of this first-of-its-kind partnership is the ambition to educate and mobilize patients to be proactive in their health, talk to their doctor and imagine a healthier tomorrow. The LPGA’s commitment to empowering women on and off the course makes them the ideal partner to help us amplify patient voices and break down barriers to care.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDX:
- Ardelyx Earnings Call: IBSRELA Fuels Growth Story
- Midday Fly By: Supreme Court strikes down Trump tariffs
- Ardelyx price target raised to $18 from $10 at H.C. Wainwright
- Ardelyx: Strong Ibsrela Momentum, De-Risked CIC Upside, and Patent-Backed Undervaluation Support Buy Rating
- Ardelyx reports Q4 EPS 0c, consensus 1c
